---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-038711"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:18:28.737492+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO reports Q4 net loss $51.2M; BLA for RGX-121 submitted, Nippon Shinyaku partnership closed

## Summary
- Net loss $51.2M ($1.01/sh) in Q4 2024 vs $62.9M; full year $227.1M ($4.59/sh) vs $263.5M. Revenue $83.3M vs $90.2M.
- BLA for RGX-121 (MPS II) submitted; FDA approval expected 2H 2025. Nippon Shinyaku deal closed: $110M upfront, up to $700M milestones.
- RGX-202 Duchenne pivotal trial nearly 50% enrolled; completion expected 2025, BLA mid-2026. Phase I/II data show favorable safety and functional improvement.
- Cash and securities $244.9M at Dec 31, 2024 (vs $314.1M). With $110M Nippon upfront, cash runway into 2H 2026.

## SEC filing metadata
- accession: 0000950170-25-038711
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000095017025038711/0000950170-25-038711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000095017025038711/rgnx-20250313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-038711
- JSON: https://secwatch.observer/filing/0000950170-25-038711.json
- Plain text: https://secwatch.observer/filing/0000950170-25-038711.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.